Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PF-06651600 Placebo Clear all
Terminated Phase 2 Interventional Results available

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

NCT04517864
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Huntington Beach, California • Irvine, California • Boca Raton, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 23, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

NCT03715829
View directory record Official record
Conditions
Active Non-segmental Vitiligo
Interventions
PF-06651600, placebo, PF06700841, narrow-band UVB phototherapy
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
40
States / cities
Huntington Beach, California • Irvine, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 23, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

NCT02974868
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600, PF-06700841, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
39
States / cities
Birmingham, Alabama • Santa Ana, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 25, 2020 · Synced Sep 23, 2026, 2:10 AM EDT
Active, not recruiting Phase 2 Interventional

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

NCT07228390
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 23, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

NCT02958865
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-06651600 or Placebo, PF-06700841 or Placebo, PF-06700841, PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
60
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 23, 2026, 2:10 AM EDT
Completed Phase 2Phase 3 Interventional Results available

PF-06651600 for the Treatment of Alopecia Areata

NCT03732807
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 23, 2026, 2:10 AM EDT
Recruiting Phase 3 Interventional

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 23, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

NCT02969044
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Northridge, California • St Louis, Missouri • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 23, 2026, 2:10 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 23, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

NCT03395184
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-06651600 Placebo, PF-06651600, Placebo PF-06700841, PF-06700841
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
57
States / cities
Dothan, Alabama • Beverly Hills, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 23, 2026, 2:10 AM EDT